Vaxxas, the developer of the Nanopatch vaccine delivery technology, has appointed David Hoey as chief executive. He also joins the company's board of directors.
Hoey has more than 20 years of executive-level experience in North America, spanning business development, licensing, strategic planning and financing for technology companies, including his most recent position as board member and vp of business development at PathoGenetix.
With this appointment, Vaxxas is establishing operations in Cambridge, Massachusetts, US to expand access to global pharmaceutical partners and complement the company’s research and development operations based in Queensland, Australia.
‘We are extremely pleased that David, a proven leader in the life sciences industry, has become Vaxxas’ ceo and was attracted by the exceptional potential of Vaxxas’ Nanopatch to enable a new class of next-generation vaccines,’ said Paul Kelly, chairman of Vaxxas. ‘David’s ability to create strong partnering alliances and success in business strategy will be a great asset as Vaxxas capitalises on the broad set of opportunities for its proprietary Nanopatch technology.’
Hoey said: ‘Our strategy is to partner with leading pharmaceutical players to optimise their next-generation and existing vaccines, as well as being a platform to enable whole new classes of vaccines and immunotherapies.’
The company’s first collaboration is with Merck.
